BNP Paribas Financial Markets
ANTX icon

BNP Paribas Financial Markets’s AN2 Therapeutics ANTX Stock Holding History

BNP Paribas Financial Markets’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.3K Sell
10,185
-19,893
-66% -$85.6K ﹤0.01% 4885
2026
Q1 		$103K Buy
30,078
+29,775
+9,827% +$61.5K ﹤0.01% 4359
2025
Q4 		$345 Hold
303
– – ﹤0.01% 5511
2025
Q3 		$385 Sell
303
-9
-3% -$10 ﹤0.01% 5331
2025
Q2 		$331 Hold
312
– – ﹤0.01% 5256
2025
Q1 		$424 Hold
312
– – ﹤0.01% 5154
2024
Q4 		$431 Buy
+312
New +$378 ﹤0.01% 5185

Other funds holding ANTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LCM
Landscape Capital Management Englewood, New Jersey $1.54B AUM 30.95% 1-Year Est. Return

BNP Paribas Financial Markets's ANTX Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its AN2 Therapeutics (ANTX) stake by 66% in Q2 2026, selling an estimated $85.6K and leaving 10,185 shares worth $49.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4885.

BNP Paribas Financial Markets first reported a position in ANTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $103K in Q1 2026. 37 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • BNP Paribas Financial Markets held 10,185 shares of AN2 Therapeutics worth $49.3K as of Q2 2026.
  • BNP Paribas Financial Markets sold 19,893 AN2 Therapeutics shares in Q2 2026, an estimated $85.6K.
  • AN2 Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4885 holding.
  • BNP Paribas Financial Markets first reported a position in AN2 Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • BNP Paribas Financial Markets's AN2 Therapeutics position peaked at $103K in Q1 2026.
  • 37 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.